Capsigen, Inc.

Industry

  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Drug Discovery Technologies
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
See more in Biomedtracker

Latest on Capsigen, Inc.

Scrip

AstraZeneca’s LogicBio Buyout Will Give Other Troubled Gene Therapy Companies Hope

 
• By Andrew McConaghie

AstraZeneca is to spend around $68m to acquire the beleaguered LogicBio Therapeutics and its gene therapy platform – a generous payout which could provide a template for further deals in the space.

Scrip

Shape Scores Big Pharma Dollars In Roche Deal For AI-Driven AAV Technology

 
• By Alaric DeArment

Fresh off its more than $100m series B venture capital round, Shape Therapeutics, Inc. has attracted a major partner – Roche Holding AG – to help develop its adeno-associated viral (AAV) vector ge

Scrip

Shape Therapeutics’ Big Financing Shows Growing Interest In Novel Capsids

 
• By Alaric DeArment

Shape Therapeutics, Inc. is the latest gene therapy-focused company to raise a large amount of capital with the aim of developing adeno-associated viral (AAV) vector-based gene therapies that offer i

Scrip

Deal Watch: Roche To Try Pieris’s Anticalins In Respiratory, Ophthalmic Indications

 
• By Joseph Haas and John Davis

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Genentech/Pieris Pact Follows Abandoned